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RELAPSE IN TUBERCULOSIS
S.P. TRIPATHY**
At the outset I would like to express my
sincere gratitude to the Tuberculosis Association
of India for having bestowed upon me the
coveted Wander-TAI Oration Award. When
I think of the illustrious personalities who have
preceded me I begin to have doubts as to whether
I will be able to do justice to today’s occasion. If
I fail to come up to your expectations it will
not be because of lack of honest efforts on my
part–it is because I neither have the scientific
stature nor the grey hairs which my predeces-
sors had. I sincerely hope you will view it in
the proper spirit and condone any lapses in
my presentation.
We are about to celebrate the centenary of
the discovery of the tubercle bacillus by Robert
Koch. It is less than 4 decades since we have
had the benefits of chemotherapeutic agents
with specific activity against tuberculosis. Never-
theless, the decades following the discovery of
streptomycin by Waksman in 1943 have seen
spectacular achievements in the chemotherapy
of tuberculosis. We now have several antituber-
culosis drugs–isoniazid, rifampicin, streptomy-
cin, pyrazinamide, PAS, ethambutol, thiaceta-
zone, ethionamide and a few other drugs.
Isoniazid is by far the most potent and most
effective drug with a bactericidal activity, with
rifampicin being a close second. Streptomycin
and pyrazinamide also have bactericidal activity,
and like isoniazid and rifampicin, cause death
of tubercle bacilli. Drugs such as PAS, ethambu-
tol and thiacetazone have a bacteriostatic
activity, that is, they prevent the multiplication
of the bacilli, so that the elimination of the
bacilli would depend upon the defence mecha-
nism of the host; their utility is limited to their
being companion drugs given in combination
with isoniazid with the object of preventing the
multiplication of isoniazid-resistant mutants.
The present day management of tuberculosis
consists of treatment with a combination of iso-
niazid with at least one other drug in appro-
priate dosages and rhythms for periods upto
24 months. With a judicious choice of drug regi-
mens containing isoniazid and other drugs it is
possible to produce rapid sputum conversion to
negativity and to eliminate the possibility of
emergence of drug-resistance ; further, patients
attaining bacteriological quiescence continue to
have quiescent disease even after stopping che-
motherapy. With inadequate chemotherapy, on
the other hand, failures may manifest in one or
more ways-sputum may fail to become culture
negative, drug-resistance may emerge, or sputum
conv rsion occurs during treatment but culture
becomes positive again after treatment is
discontinued, that is, the patient has a bacterio-
logical elapse. With the advent of highly
effective chemotherapeutic regimens with practi-
cally 100 % efficacy, bacteriological relapse has
become the most crucial factor in determining
the relative merits of chemotherapeutic regimens.
I have, therefore, chosen the subject of relapse
for today’s oration.
Antituberculosis drugs have two major
roles-they are required to kill dividing bacilli,
so that the patient becomes sputum negative
and non-infectious; they are also called upon to
kill bacilli which have a tendency to persist
during chemotherapy and give rise to bacterio-
logical relapses later on. The speed of sputum
conversion and relapse rates are thus good
measures of the bactericidal and sterilising acti-
vity of regimens and drugs. Table 1 summarises
f ndings from patients in East Africa1 and Hong
K ng2 and presents the bactericidal activity of
various regimens measured in terms of propor-
tions of sputum positive cases who converted to
negativity by the end of 2 months of chemo-
therapy.
TABLE 1
Bactericidal activity on dividing bacilli in
sputum positive patients
SH 49
–
SHT 49
–
SHZ 66
–
SHZR 95
–
SHER 81
–
S–Str ptomycin H–Isoniazid
T–Thiacetazone Z–Pyrazinamide
R–Rifampicin E–Ethambutol
*Wander - T.A.I. Oration, 1980.
**Director, Tuberculosis Research Centre, Madras-31.
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The regimen SH produced sputum conver-
sion in 49 per cent of patients. The addition of
thiacetazone, a bacteriostatic drug, to the SH
regimen, made no difference to the bactericidal
activity of the regimen. Pyrazinamide, however,
made a substantial contribution raising the
proportion to 66 per cent. Rifampicin further
enhanced the bactericidal activity, with 95 per
cent of the patients becoming culture negative.
Ethambutol, another bacteriostatic drug, was
clearly inferior to rifampicin.
Table 2 presents data on the ability of the
drug regimens to kill persisting bacilli and thus
produce sterilisation of lesions and prevent the
occurrence of bacteriological relapses after
stopping chemotherapy.
Table 2
Sterilising activity on persisting bacilli
6SH* 6 29
6SHT 6 22
6SHZ 6 8
2SHRE/4S2H2E2** 6 21
2SHRZ/4S2H2Z2 6 7
2SHRE/6S2H2E2 8 10
2SHRZ/6S2H2Z2 8 4
studies conducted at the Tuberculosis Research
Ce tre, Madras, under the auspices of the Indian
Council of Medical Research in collaboration
with the British Medical Research Council,
the World Health Organisation and the Govern-
ment of Tamil Nadu. In addition, the British
Medical Research Council has also participated
in collaborative studies in East Africa, Hong
Kong, Singapore and other countries. Conse-
quently, we now have a wealth of information
on relapses, why they occur and how they can
be prevented. We shall discuss the findings,
separately in tuberculosis patients who were
initially bacteriologically positive, and those who
were initially bacteriologically negative but
had active pulmonary tuberculosis requiring
treatment.
Sputum positive cases
Most of the controlled clinical studies in
pulmonary tuberculosis have been carried out
on patients who were bacteriologically positive.
Since its inception in 1956, the Tuberculosis
Research Centre in Madras has carried out a
series of controlled clinical trials in newly
diagnosed previously untreated bacteriologically
positive cases of pulmonary tuberculosis resid-
ing in Madras City. Most of them were treated
with drug-regimens on an ambulatory basis for
durations of 1 year in the earlier studies, and 3
to 7 months in the recent studies. All these
patients had culture-positive tuberculosis, with
over 90 per cent having positive smears; nearly
all had cavities, with about 70 per cent of them
having moderate or extensive cavitation and
moderate or gross disease as assessed radiologi-
cally. Thus, most of the patients in these studies
had extensive pulmonary pathology. The pre-
treatment characteristics of these patients have
remained more or less same during the past
25 years.
These patients were treated with drug regi-
mens for the scheduled durations and were
* The prefix indicates the number of months of che-classified as having quiescent disease if all cul-
motherapy with the regimen
** The suffix indicates the number of doses of the drug
tures during the last 2-3 months were negative
for t bercle bacilli, and the response was consi-
during the week. dered as favourable. Patients having quiescent
disease at the end of chemotherapy were followed
The addition of thiacetazone (T) to SH didupto 60 months-by monthly sputum examination
not significantly bring down the relapse rates;upto 24 months from the start of treatment and
pyrazinamide, on the other hand, brought theat 3 monthly intervals, thereafter, in order to
relapse rate down from 29 per cent to 8 per cent.determine the stability of bacteriological quies-
The contrast between pyrazinamide and etham-c nce and the relapse rates. A patient was
butol clearly shows that pyrazinamide is moreclassified as having had a bacteriological relapse
effective than ethambutol in killing persistingif 2 or more positive cultures were obtained
bacilli and thus preventing relapses. during a 6-month period. A culture was consi-
dered to be an isolated positive culture if there
Bacteriological relapses have been investi-was no other positive culture in the previous
gated extensively in the various chemotherapy6 months or in the succeeding 6 months.
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Table 3
Bacteriological Relapses following Chemotherapy with conventional 12 Mo th Doily Regimens
47
Regimen
H 100mgb.d.
or
H 200 mg b.d.
H 400mgo.d.
or
H 650 mg o.d.
H + To.d.
H + Pb.d.
H + Eo.d.
P -PAS
Total Culture Favourable Total Relapse Overall
patients negative response at patients in (%) efficacy
at 2 months 1 year (%) relapse (%)
(%) study
129 35 45 32 12 40
207 44 70 50 12 62
72 44 82 21 19 66
454 42 85 143 17 71
107 49 96 43 16 81
Table 3 summarises the results of chemothe-per c nt of the patients with quiescent disease
rapy with conventional daily regimens of iso-
niazid alone, isoniazid plus thiacetazone, iso-
had a relapse. As a consequence of the relapses
the verall efficacy of the regimens was consi-
niazid plus PAS or isoniazid plus ethambutol,
for a duration of one year. The regimens had
derably reduced, to 81 per cent with the best
efficacies ranging from 45 per cent to 96 per
daily regimen, ethambutol plus isoniazid, and to
8  cent with the best intermittent regimen,
cent. streptomycin plus isonianid twice a week.
The regimens of isoniazid alone were asso-
ciated with relapses in 12 per cent of cases. It
is significant that the two-drug combinations of
isoniazid plus thiacetazone, PAS or ethambutol
were associated with equally high relapse rates–
16-19 per cent. Thus, ethambutol, PAS and
thiacetazone did not contribute to the killing of
persisting bacilli which give rise to relapses.
This is also seen in the proportions of patients
who were culture negative at 2 months–
namely, 44 per cent with regimens of isoniazid
alone (450 mg or 650 mg daily), compared with
42-49 per cent with the two drug regimens.
Table 4 summarises similar findings in
Madras patients treated with supervised inter-
mittent regimens for a duration of 12 months,
Even these regimens did not have high bacteri-
cidal activity: less than 50 per cent became cul-
ture negative by the end of 2 months and 9-15
As stated earlier, nearly all the patients had
cavitated disease at the start. In many, the cavi-
ties disappeared during treatment; there were
also patients who had a favourable response to
tre ment but were left with residual cavities
lined by fibrous tissue or epithelial cells, i.e.,
‘open negative syndrome’. Data on the frequency
of r lapses in those with residual cavitation and
in those without are presented in Table 5.
There is evidence that with conventional regi-
mens, the relapse rates were higher in patients
with residual cavitation, with roughly a fifth
of the patients having a relapse before the end
of 5 years.
Table 6 summarises the findings of several
studies on relapse in Madras patients 3-6. It
will be seen that 18 per cent of 296 patients
treated with 12-month regimens had a relapse;
in about two-thirds of them the relapse occurred
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Table 4
Bacteriological Relapses following Chemotherapy with intermittent 12 Mon h Regimens
Regimen
SHOW or
SHZOW
SH/SHOW
SPH/SPHOW
SHTW
Total Culture Favourable Total Relapse
patients negative at response atpatients in (%)
2months       1 year (%)relapse
(%) study
224 41 70 30 19
261 47 88 197 15
174 49 89 47 13
199 42 94 55 9
Table 5
Relationship between Residual Cavitation at the end of Chemotherapy and Relapse
Overall
efficacy
(%)
63
75
77
86
Cavitation No cavitation
Regimen
Total Relapse Total Relapse
No. % No. %
Isoniazid alone 11 2 18 44 3 7
PH, EH or TH 70 14 20 138 21 15
Intermittent S+H regimens 160 30 19 169 10 6
Table 6
Bacteriological relapses daring 4 + Years after Chemotherapy for 1 Ye r in Madras Patients
Total relapses in 4 year Year of relapse Relapse
Report Total period with H
patients sensitive
No. % 2nd 3rd, 4th and cultures
5th
Dawson et al (1966) 61 8 13 5 3 6
Evans et al (1969) 87 15 17 9 6 13
Ramakrishnan et al (1969) 54 11 20 5 6 9
Nazareth et al (1966) 94 20 21 14 6 18
ALL 296 54 18 33 21 46(86)
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during the second year i.e., during the first 12
months after stopping chemotherapy. In all,
86 per cent of the patients relapsed with cultures
sensitive to isoniazid, so that they could be
retreated with regimens of conventional che-
motherapy such as streptomycin plus isoniazid.
Isolated Positive Cultures
We have seen that among patients who had
attained bacteriological quiescence following 1-2
years of chemotherapy with standard regimens,
about 18% had a bacteriological relapse, i.e.,
they excreted 2 or more cultures during a 6-
month period. In addition, several patients
excreted isolated positive cultures. Thus, 73
(17%) of 434 patients excreted 1 or more isola-
ted positive cultures during 3-4 years after
completion of chemotherapy (Table 7).
Table 7
Isolated postive cultures during 4 years after chemotherapy
for 1-2 Years in Madras
I
Dawson et al 126
(1966)
Evans et al 180
(1969)
Ramakrishnan et al128
(1969)
ALL 434
Patients with
isolated positive
cultures
 No. %
18 14
29 16
26 20
73 17
Isonia-
zid
sensitive
10a
18b
16
44 65%
after 12 months of the scheduled chemotherapy.
The results showed that maintenance therapy
with isoniazid alone daily or isoniazid plus
streptomycin once a week for 1 year completely
prevents the occurrence of relapses, Thus, if
chemotherapy with standard drugs were to be
continued for 24 months it would be possible
to completely eliminate relapses. This however
poses logistic problems and also problems of
patient compliance. Under field conditions in
I dia and other developing countries only
about 50 per cent of the patients complete their
chemotherapy-it would be impossible to orga-
nise an effective treatment programme with a
24-month regimen because of lack of patient
compliance. For any modification in the Tuber-
culosis Programme to be meaningful one should
be thinking in terms of reduction in the duration
of chemotherapy, rather than increasing the
duration, without compromising on the effi-
cacy of the regimens. With the bactericidal
antituberculosis drugs now available, it is
possible to evolve effective short-course regimens
with high efficacy and no relapse rates. Question
is : Which drugs, and how long should they be
given.
Table 8 summarises the relative bactericidal
properties of four antituberculosis drugs as
assessed by their activities in laboratory studies
in vitro against cultures of tubercle bacilli,
and in vivo against experimental tuberculosis
in mice and in guinea-pigs.
Table 8
Relative bactericidal activity of 4 main drugs used in Short–
Course Chemotherapy
a 3 cultures were not tested
b 2 cultures were not tested
Taking into consideration the finding that
about 18 % patients had a bacteriological relapse
(with at least 2 positive cultures) it would seem
that about a third of the patients who had
attained quiescence following standard chemo-
therapy excreted tubercle bacilli in their sputum
on at least one occasion during the 3-4 year
period of follow-up.
In our studies at Madras, a proportion of
patients were given maintenance chemotherapy
Drug
Isoniazid
Rifampicin
Streptomycin
Pyrazinamide
*H 5.2–5.6
**Drugs given in very high dosages
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It is clear that all the four drugs have bacteri-
cidal activity;isoniazid and rifampicin have
very high activity, while that of streptomycin
and pyrazinamide is relatively less.
We now have a wealth of information on
the relative efficacy of these drugs in treatment
of tuberculosis in man, and the clinical results
are generally in conformity with the laboratory
findings. These four drugs have now been regar-
garded as the drugs of choice in the formula-
tion of short course regimens.
Relationship between Drug action and Physiologi-
cal state of Bacilli
The available data indicate the existence of
at least three types of bacterial populations
according to their anatomical location.7 The
first is a population of actively growing tubercle
bacilli present in the liquefied caseous material.
This is by far the largest fraction of the total
bacterial population and contributes to practi-
cally the entire bulk of bacilli excreted in the
sputum in untreated patients and in the early
months of treatment. These bacilli are acted up-
on by isoniazid, and, to a smaller extent, by
rifampicin and streptomycin. By virtue of the
largeness of the bacterial population, drug-resis-
tant mutants are usually present in this fraction.
Combinations of 2 or more bactericidal drugs
are therefore, necessary to effectively prevent
the survival and selection of drug-resistant
mutants.
The second is the population of bacilli
situated within the macrophages in an acidic
milieu; they grow very slowly, and escape the
action of all anti-tuberculosis drugs except
pyrazinamide. The third population consists
of small numbers of bacilli which are present
extra-cellularly in solid caseous lesions and
multiply slowly and intermittently; rifampicin
is the only drug which acts on this population.
There is possibly a fourth population of dormant
bacilli not killed by any drug. Since all these
populations exist in the lesions, it is necessary
to give at least 3 drugs, isoniazid, rifampicin and
pyrazinamide, and possibly streptomycin as well
to ensure that relapses do not occur. Regimens
which do not contain rifampicin and pyrazina-
mide may still produce sputum conversion by
eliminating the first bacterial population but
will be associated with persistence of the remain-
ing populations with their subsequent multi-
plication, giving rise to positive cultures; these
tend to be only single positive cultures (isolated)
in many patients if the host defence is able to
limit the bacterial multiplication. In a propor-
tion of patients the defence mechanism might
fail, in which case the patient excretes bacilli
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rep atedly, and is classified as a bacteriological
relapse. Since the persisting bacilli in the special
populations have escaped the action of drugs,
there has not been the requisite ‘elimination’
of the drug-sensitive members of the population
for the emergence of drug-resistance. Tubercle
bacilli isolated from patients who have bacterio-
logical relapses, therefore, are usually sensitive
to he drugs with which the patients have been
treated.
We have seen that many patients treated
with full courses of standard regimens occa-
sionally excrete tubercle bacilli, i.e., isolated
positive cultures. As we will see later, such
isolated positive cultures occur with almost
similar frequency in patients who have been
treated with effective short course regimens
containing the four bactericidal drugs. The
exa t significance of such cultures is not yet
known  They possibly arise from the persistence
of dormant bacilli in the fourth population
referred to earlier. At the moment such cultures
do not appear to have any clinical significance,
since they tend to be limited to single cultures.
Relapses in Short Course Chemotherapy
Combinations of bactericidal drugs adminis-
tered to patients with drug-sensitive cultures are
highly effective with practically no bacteriological
failures during treatment, so that virtually 100
per cent of the patients have a favourable
response at the end of chemotherapy with rifam-
picin plus isoniazid or similar potent combina-
tions. Hence, a criterion of a favourable res-
ponse to treatment cannot discriminate one
regim n from another. The crucial question is
wh ther the quiescence attained is stable, i.e.,
the patient does not have a bacteriological
lapse. A close and intensive follow-up during
the past-treatment phase is thus an essential
part of any controlled clinical trial of short
course chemotherapy.
A regimen of rifampicin plus isoniazid
daily for 9 months, with an initial daily supple-
ment of streptomycin or ethambutol during the
first two months, is associated with a 0 per
cent relapse rate during 2 years of follow-up
nd is now standard short-course chemotherapy
n technically advanced countries. This regimen,
however, is expensive because of the cost of
ifampicin. Controlled clinical studies in East
Africa, Hong Kong,Singapore and other
countries have shown that with a proper choice
of drugs the duration of chemotherapy can be
reduced to 6 months without increasing the risk
of relapse. Initial intensive chemotherapy with
3 or 4 drugs for 2 months effectively eliminates
the bacterial populations so that thereafter
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maintenance chemotherapy with two drugs for
a further 4 months ensures sputum conversion
in all patients and a virtual freedom from re-
lapse.
The First Madras Short Course study was
based on the results of studies in East Africa,
Hong Kong and Singapore. In this study,
(Table 9) all patients received an initial intensive
chemotherapy with SHRZ (for 2 regimens)
or SHZ (for one regimen) daily for two months,
followed by twice-weekly SHZ for 3 months
or 5 months, so that the total duration of
chemotherapy was 5 months or 7 months8.
All the 3 regimens were associated with low
relapse rates (Table 10). The 7-month rifampicin
regimen had no relapses; reducing the duration
 to 5 months or the removal of rifampicin from
the regimen carried a small penalty in the form
of 3-5 per cent relapses. The findings of the non-
rifampicin regimen, in particular, are of consi-
derable interest since this regimen is relatively
inexpensive and, therefore, can be useful. in
developing countries.
Table 9
Madras Short Course studies-Drug Regimens
The Second Madras Short Course Study9
investigated the efficacy of a 3-month daily regi-
men of SHRZ in comparison with two other
5-month regimens (Table 9). The 3-month regi-
men had a relapse rate of 12 per cent, so that the
overall efficacy of the regimen is over 85 per
cent. This result is highly encouraging, since
the duration of the regimen is only 3-months
Regimen Total duration
2SHRZ/3 S2H2Z2 5 Months
FIRST STUDY 2SHRZ/5 S2H2Z2 7 months
2SHZ/3S2H2Z2 7 months
3SHRZ 3 months
SECOND
STUDY 3SHRZ/2S2H2Z2 5 months
3SHZ/2S2H2Z2 5 months
and hence patient compliance is likely to be
high. The conventional 12-month daily regimens
of Thiacetazone plus isoniazid (TH) or PAS
plus isoniazid (PH) are associated with 15-20
per cent. failures during treatment, about 20
pe  cent relapses afterwards, and a low patient
compliance. There is thus a priori reason to
believe that the results of the 3-month MSHZ
regimen will be better than with the 12-month
PH or TH regimens under field conditions.
Table 10
Results of Madras Short Course Studies
(Patients with drug sensitive cultures)
Daily phase
(months)
Twice weekly
phase (months)
Total Favourable res-Relapse during
patients ponse at the end18 months (%)
of treatment (%)
FIRST STUDY
SECOND STUDY
RSHZ (2)
RSHZ (2)
SHZ (2)
RSHZ (3)
RSHZ (3)
SHZ (3)
SHZ (3)
SHZ (5)
SHZ (5)
–
SHZ (2)
SHZ (2)
129 100 5
132 100 0
269 100 3
139 98 12
137 100 3
153 100 10
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Isolated positive cultures
Earlier, it had been stated that many quies-
cent patients who had been treated with standard
chemotherapy excreted isolated positive cultures
during the follow-up phase. This was also true
of patients who attained quiescence following
short-course chemotherapy. Thus, in the First
Madras Short Course study, 135, i.e. 25%
of the 530 patients followed up excreted isolated
positive cultures-they included 38 (30 %)
patients on the 2SHRZ/3 S2H2Z2 regimen, 38
(29%) on the 2SHRZ/5 S2H2Z2 regimen, and
59 (22%) on the 2SHZ/5 S2H2Z2 regimen. Their
exact clinical significance is as yet uncertain.
Role of individual drugs in the prevention of
relapse
Relapse rates associated with short-course
regimens of varying durations and containing
different combinations of drugs provide valuable
information on the role of each drug in the
prevention of relapses.
It is generally accepted that isoniazid is the
drug par excellence. Given alone in high dosage,
it leads to sputum conversion in about 70 per
cent of patients, and most of the patients who
convert remain free from relapse. Because of
ethical reasons it is not possible to establish the
relative efficacy of isoniazid and any other
antituberculosis drug by conducting controlled
clinical trials with regimens with and without
isoniazid. There is no such limitation in the case
of other drugs. Results of controlled trials with
short-course regimens provide clear evidence
of the role of several antituberculosis drugs in
the prevention of relapse.
Role of pyrazinamide
Table 11 summarises the findings on 6 pairs
of regimens studies in East Africa1,10,11 nd
Singapore.12 The addition of pyrazinamide daily
to a 6-month regimen of streptomycin plus
isoniazid (SH) substantially reduced the relapse
rate from 29 per cent to 8 per cent. Such a
beneficial effect was noted when the administra-
tion of pyrazinamide was limited to the first
two months. The data on 4-month regimens
suggest that the continued administration of
pyrazinamide beyond 2 months does not influ-
ence the relapse rates.
In summary, pyrazinamide administered
during the first 2 months effectively reduces
relapse rates but continued administration
beyond 2 months does not confer any additional
benefit.
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Table 11
Role of pyrazinamide in Short Course Chemotherapy
Place of studyRegimen
East Africa
East Africa
East Africa
6SH
6SHZ
2SHR/TH
2SHRZ/TH
2SHR/TH
2SHRZ/TH
Eas  Africa
East Africa
Singapore
2SHRZ/HRZ
2SHRZ/HR
2SHRZ/HZ
2SHRZ/H
2SHRZ/HRZ
2SHRZ/HR
Duration Relapses
(months) (%)
29
8
18
13
6
0
14
11
28
30
10
5
Role of streptomycin
Data on the role of streptomycin in the
prevention of relapse are summarised in Table
12. The high relapse rate of 29 per cent asso- 
ciated with the 6SH regimen in East Africa
shows that streptomycin is a poor companion
drug to isoniazid, unlike rifampicin. The contrast
between the 2HRZ/H and 2SHRZ/H regimens11
as well as that between 6 HR and 6SHR
regimen13 however, suggests that the addition
of str ptomycin reduces the relapse rates, but
only marginally.
Role of rifampicin
special bacterial population on which rifampicin
Data on the role of rifampicin in short-
course regimens are summarised in Table. 13.
The addition of rifampicin to SH or SHZ
reduces the relapse rates. The contrast between
the regimens 2SHRZ/H and 2SHRZ/HR clearly
shows that, unlike pyrazinamide, rifampicin
continues to make an important contribution
in the continuation phase. This suggests that the
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Table 12
Role ofstreptomycin in Short Course Regimens
Regimens
2HRZ/H
2SHRZ/H
6 H R
6 SHR
6 S H
Duration
(months)
Relapses
(%)
41
30
8
4
29
Table 13
Role of rifampicin in Short Coarse Regimens
Place of study Regimen
East Africa1
Madras8
Madras9
East Africa11
6 S H
6 SHR
2 SHZ/S2H2Z2
2 SHRZ/S2H2Z2
3SHZ/S2H2Z2
3SHRZ/S2H2Z2
2SHRZ/H
2SHRZ/HR
Duration
(months)
1Relapses
29
4
3
0
10
3
29
4
acts exclusively requires a longer period of
exposure to ensure its elimination.
Role of bacteriostatic drugs
Data from East Africa and Hong Kong,
already presented in Table 2 indicate the role
played by bacteriostatic drugs such as thiace-
tazone and ethambutol in short-course chemo-
therapy. The addition of thiacetazone to SH
did not reduce the relapse rate significantly,
while the addition of pyrazinamide did so subs-
tantially. The ethambutol regimen studied in
Hong Kong was associated with a relapse rate
of 21 per cent, while the corresponding pyrazi-
namide regimen had a relapse rate of 7 per cent.
There is thus clear evidence that bacteriostatic
drugs such as thiacetazone and ethambutol
are associated with high relapse rates, and have
no place in short-course regimens.
Rhythm of administration of drugs
Intermittent chemotherapy has several ad-
vantages over conventional daily regimens.
Firstly, the drugs can be given under full super-
vision, and this eliminates concealed drug-
irregularity; secondly, adverse reactions due to
drugs occur less frequently when drugs are given
intermittently, and finally, intermittent regimens
often less expensive than the corresponding
daily regimens, particularly in the case of regi-
mens which employ rifampicin.
Table 14 presents data from a controlled
trial in Hong Kong14, comparing the results of
daily, twice-weekly and thrice-weekly adminis-
tration of drugs. The results show that there is
little change in the relapse rates when the
interval between successive doses is increased
from one day to two days or to three days.
Influence of the duration of short-course chemo-
therapy on the relapse rates
There is evidence from many studies that
Table 14
Rhythm of administration of drugs in Short Course
Chemotherapy
Regimen Duration
(months)
Unfavourable Relapse
response at (%)
the end of
treatment
(%)
SHZ
S3H3V3
S2H2Z2
SHZ
S3H3V3
S2H2Z2
6 0 18
1 24
4 21
9 0 5
0 6
1 6
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the relapses associated with some short-course
regimens can be prevented by continuation of
the regimen by a further 2 or 3 months (Table
15). The two 4-month regimens studied in
Singapore12 had relapse rates of 5 % and 10 %;
extending the duration of the continuation phase
by another2 months virtually eliminated the
occurrence of relapses. While the near-sterilis-
ing effect of 6-month chemotherapy stands out
clearly, there is an important message for a
developing country like India-reducing the
duration of chemotherapy from 6 months to
4 months has resulted in only a small penalty-
the over-all efficacy of the 4-month regimen is
still high enough forapplication in routine
chemotherapy.
Table 1.5
Duration of short-course chemotherapy
Place of Study Regimen Duration Bacterio-
of Chemo-    logical
therapy relapse
(months) (%)
I
Relapse in patients who had drug-resistant cultures
initially
In the two short-course studies reported
from Madras there were 214 patients with resis-
tance to Streptomycin or to isoniazid or to
both drugs. Their response to treatment, as well
as the relapse rates in those who had a favourable
response, are presented in Table 16. It will be
seen that the relapse rates were low and similar
in patients treated with the rifampicin and the
Singapore12 2 SHRZ/HRZ 4 10
6 0
2 SHRZ/HR 4 5
6 1
Madras8 2 SHRZ/S2H2Z2 5 5
7 0
Hong Kong14 S2H2Z3 6 25
9 9
Hong Kong2 4S3H3T3Z2/S2H2 6 6
Z2 8 1
non-rifampicin regimens, even though the res-R lap e in patients with smear-negative pul-
ponse to treatment was substantially inferior   monary tuberculosis
in the case of the non-rifampicin regimen.
Whether resistance was to one drug or bothPatients with smear-negative pulmonary
drugs or whether resistance was to strepto-disease in general have less extensive disease
mycin or to isoniazid did not also have anyand less number of bacilli in their lesions than
influence on the relapse rates. patients with smear-positive disease. One may
Table 16
Response of patients with initial drug-resistance in the two Madras Short-Course Studies
Resistance
Non-rifampicin regimens
Total Favourable Relapse
response
S only 17 16 1
H only 25 16 1
SH 33 7 0
Either drug
Rifampicin regimens
Total Favourable
response
Relapse
32 32 4
48 43 2
59 44 2
139 119 8(7)
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Table 17
Relapse in smear-negative-patients
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Culture result on
admission
Negative
Positive,
drug-sensitive
Group
Selective chemotherapy
2 SHRZ
3 SHRZ
SPH/S2H2
2 SHRZ
3 SHRZ
SPH/S2H2
No. of patients assessedBacteriological relapses
by 12 months ( %)
181 34
175 1
168 1
167 1
73 14
74 1
83 0
expect that sterilisation of their lesions could be
achieved with less intensive chemotherapy and
for shorter durations. There is, however, very
little scientific evidence in support of this con-
tention. The Tuberculosis Research Centre
participated in a cooperative study in collabora-
tion with the Hong Kong Chest Services and
the British Medical Research Council.15 Symp-
tomatic patients with smear-negative, radiolo-
gically active pulmonary tuberculosis were
admitted to a controlled clinical trial and
randomly allocated to 4 groups –
(a) A selective chemotherapy group-the
patients were placed under observation
and carefully followed up by periodic
bacteriological examination. Treatment
was started only if the patient’s sputum
yielded tubercle bacilli on culture or if
there was clinical or radiographic deterio-
ration warranting initiation of chemo-
therapy; such patients were prescribed
a standard12-month regimen of SPH/S2H2.
(b) 2 SHRZ group: The patients received
SHRZ daily for a period of 2 months
(c) 3 SHRZ group: The patients received
SHRZ daily for 3 months; and
(d) SPH/S2H2 (Control Group) : The patients
received PH daily for 12 months with
a supplement of Streptomycin daily
for the first 3 months.
Of 1072 patients with negative smears,
64 % had all cultures negative, while the remain-
ing 36% had at least one culture positive. The
patients were followed up by regular monthly
bact riological examination. The results are
presented in Table 17 separately for those
patients with one or more positive cultures
fully sensitive to streptomycin and isoniazid,
and f r those who were culture negative.
Thirty-four percent of patients in the Selec-
tive Chemotherapy Group had a break-down,
giving rise to positive cultures, and were started
on treatment with SPH/S2H2. In contrast, the
relapse rate was 1% each of the three groups
treated with drugs. Thus, the two short-
course regimens had prevented relapse rates
of the order of 30 %.
Considering the results in patients who had
one or more positive cultures on admission,
it is seen that while there were no failures among
those treated with the standard SPH/S2H2
regimen for 12 months, 14 % of the patients on
2 SHRZ and 7% of those on 3 SHRZ had a
bacteriological relapse.
In summary, even 3 months of intensive
daily chemotherapy with the 4 drugs SHRZ
is inadequate in patients who are smear-negative
but culture positive;a longer duration of
chemotherapy is necessary for complete preven-
tion of relapse in such cases. However, 2-3
months of chemotherapy effectively prevents the
occurrence of relapses in patients with smear-
negative culture-negative disease.
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General features of relapse
We have by now quite a large body of data
on relapses so that we can make some general
conclusions.
(1) Relapses generally tend to occur within
the first year after stopping chemotherapy.
(2) In the case of patients who had drug
sensitive cultures at the start of chemo-
therapy, relapses occur with drug-sensi-
tive cultures (the so-called relapses occu-
rring during chemotherapy are actually
not relapses–they are manifestations of
a fall and rise phenomenon; such cul-
tures are usually drug-resistant).
(3) Since their cultures are usually sensitive
to isoniazid and streptomycin, patients
who have a relapse can be successfully
retreated either with short-course regi-
mens or with conventional 12-month
regimens containing isoniazid.
(4) Relapse rates are higher with regimens
which include bacteriostatic drugs than
with regimens containing bactericidal
drugs.
(5) Relapse rates are similar in patients who
have drug-sensitive cultures and in those
who have drug-resistant cultures on ad-
mission.
(6) It is not clear as to what factors are
responsible for relapse occurring in an
individual patient. There are indications
that the initial bacterial content, the
extent of disease initially, the month of
sputum conversion and the presence of
residual cavitation at the end of chemo-
therapy have some role. The immunolo-
gical status of the host may play a major
role and may determine which patient
will have a relapse and when.
So far, we have been discussing the occur-
rence of relapses in tuberculous patients who had
been successfully treated with full courses of
antituberculosis drugs and had attained bacterio-
logical quiescence. Such relapses which occur
due to a break-down of the host defence mecha-
nism represent only a small part of the tuber-
culosis problem in the country. A similar situa-
tion exists on a much larger scale in infected,
tuberculin-positive, apparently healthy indivi-
duals in some of whom, for no apparent reason,
the immune mechanism is disrupted and tuber-
culosis results due to a process of endogenous
reactivation. Although such breakdowns are
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not generally termed relapses, they deserve to be
so named since they occur in more or less the
same way relapses occur in patients who had
attained quiescence following chemotherapy.
They pose a much bigger problem, since the bulk
of the cases of tuberculosis in our country come
from the tuberculin positive individuals. Thus,
in the recently concluded BCG trial in Chingle-
put, the annual incidence of disease was 20 times
higher in the tuberculin-positive group than in
the tuberculin negative group. The important
que tion is whether anything can be done to
activate the host defence mechanism so that it
effectively eliminates residual, dormant bacilli
from lesions which have apparently healed under
the influence of chemotherapy or from healed
primary complexes in apparently healthy tuber-
culin-positive individuals. This issue has now
a sumed considerable importance in view of the
lack of efficiency of BCG in protection against
baci lary forms of pulmonary tuberculosis.
Research on the immunology of tuberculosis
in general, and its relationship with relapses
and break-downs in particular, is urgently
needed so that the strategy for tuberculosis
control can be strengthened.
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